By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Incyte Corporation 

Experimental Station
Route 141 & Henry Clay Road, Building E336
Wilmington  Delaware  19880  U.S.A.
Phone: 302-498-6700 Fax: 302-425-2750


Company News
Incyte (INCY) Reports 2015 Fourth-Quarter And Year-End Financial Results, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs 2/11/2016 10:30:51 AM
Incyte (INCY) Stock Tumbles After Halting Another Jakafi Trial for Treating Solid Tumors 2/11/2016 5:49:57 AM
Incyte (INCY) Plunges on Halted Colorectal Cancer Study 1/28/2016 6:04:29 AM
Incyte (INCY) To Report Fourth Quarter/Year-End Financial Results 1/21/2016 8:24:17 AM
Eli Lilly (LLY) And Incyte (INCY) Announce Submission Of New Drug Application To FDA For Oral Once-Daily Baricitinib For Treatment Of Moderate-To-Severe Rheumatoid Arthritis 1/19/2016 6:13:17 AM
Incyte (INCY) Presents Significant Progress In Its Development Portfolio 1/11/2016 12:46:23 PM
Incyte (INCY) And AstraZeneca PLC (AZN) Announce New Lung Cancer Clinical Trial Collaboration 1/11/2016 10:17:25 AM
Incyte (INCY) To Present At The 34th Annual J.P. Morgan Healthcare Conference 12/14/2015 9:24:34 AM
Incyte (INCY) Release: Two Phase 3 Studies Reinforce Sustained Benefits Of Treatment With Jakafi (Ruxolitinib) In Patients With Myeloproliferative Neoplasms(MPNs) 12/7/2015 2:16:16 PM
Incyte (INCY) Release: Phase 3 RESPONSE-2 Study of Jakafi (ruxolitinib) Meets Primary Endpoint 12/7/2015 2:14:35 PM